Gene · 4920
ROR2: ROR family WNT receptor 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ROR2: ROR family WNT receptor 2. Genes, record 4920. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4920
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q01974 | Tyrosine-protein kinase transmembrane receptor ROR2 | 943 | 6 | Ensembl, GeneID, HGNC |
Source UniProt
Patents60
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2026128025 A2 | 2026-06-18 | 38 | Q01974 | Espacenet |
| EP 4739347 A1 | 2026-05-13 | 38 | Q01974 | Espacenet |
| JP 2026501564 A | 2026-01-16 | 34 | Q01974 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 61156 | Q01974 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 9670 | Q01974 | Espacenet |
| EP 4642808 A2 | 2025-11-05 | 34 | Q01974 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 9926 | Q01974 | Espacenet |
| JP 2025137618 A | 2025-09-19 | 95 | Q01974 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 3768 | Q01974 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 3768 | Q01974 | Espacenet |
1 to 10 of 60
See all 60 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,312
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ROR2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 12 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 12 | 2025 |
| P30CA010815 | Consolidated Basic Cancer Research Program | 7 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 5 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 4 | 2025 |
| R01CA204484 | Novel Enediyne-Based Antibody-Drug Conjugates for Cancers | 4 | 2025 |
| R35GM122485 | Understanding Signaling by Non-Canonical Receptor Tyrosine Kinases | 4 | 2025 |
| R35NS105078 | STRUCTURAL VARIATION IN NEUROLOGICAL DISEASE | 4 | 2025 |
| T32CA009171 | Training Program in Basic Cancer Research | 4 | 2025 |
| T32ES007126 | Pre- and Postdoctoral Training in Toxicology | 4 | 2025 |
1 to 10 of 1,312Source NIH's project files
See all 1,312 nih grantsPapers2,066
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting an ASCL1-WNT11-ERK feed-forward loop to overcome pyrotinib resistance in HER2-positive breast cancer. | Mater Today Bio | 2026 | 42787995 | PubTator, text mining | PubMed |
| Composition and Function of Decellularized Human Lung Extracellular Matrix from Congenital Pulmonary Airway Malformation. | J Clin Med | 2026 | 42739747 | PubTator, text mining | PubMed |
| Surface and global proteomics identify ROR2 and other proteins as potentially actionable immunotherapeutic targets in osteosarcoma. | Cell Rep | 2026 | 42647168 | PubTator, text mining | PubMed |
| Paediatric Therapeutic Development Workshop on rhabdomyosarcoma. | Br J Cancer | 2026 | 42288687 | PubTator, text mining | PubMed |
| The multifaceted roles of receptor tyrosine pseudokinases in cellular signalling. | Biochem Soc Trans | 2026 | 42267535 | PubTator, text mining | PubMed |
| MYOD1 mutation drives cancer stem cell pathways and therapy-resistance in spindle cell/sclerosing rhabdomyosarcoma. | Nat Commun | 2026 | 42236477 | PubTator, text mining | PubMed |
CRI-CCTG-0003/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021). | Cancer Treat Res Commun | 2026 | 42225005 | PubTator, text mining | PubMed |
| Meflin confers antifibrotic properties to intestinal fibroblasts in inflammatory bowel disease. | J Clin Invest | 2026 | 42154532 | PubTator, text mining | PubMed |
| Tiki2 restrains Wnt5a/Ror signaling to limit inflammation in acute kidney injury. | Commun Biol | 2026 | 41981279 | PubTator, text mining | PubMed |
| Human receptive endometrial assembloid for deciphering the implantation window. | Elife | 2026 | 41920166 | PubTator, text mining | PubMed |
1 to 10 of 2,066
See all 2,066 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/4920
GET https://conductscience.org/api/genes/v1/4920/patents?page=2